Ann M. Buchanan

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Catherine Orrell, Debbie Hagins, Elena Belonosova et al. · The Lancet HIV · 2017 · 118 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region

Ann M. Buchanan, Florida Muro, Jean Gratz et al. · Tropical Medicine & International Health · 2010 · 80 citations · Full text

Medicine, Hematology, Immunology +15

Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study

Rolando M. Viani, Theodore Ruel, Carmelita Alvero et al. · Journal of the Pediatric Infectious Diseases Society · 2018 · 43 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +16

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study

Cindy Vavro, Theodore Ruel, Andrew Wiznia et al. · Antimicrobial Agents and Chemotherapy · 2021 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models

Andrey A. Komissarov, Galina Florova, Ali Azghani et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2016 · 32 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +14